Dr. Bruce D. Carter Joins Scientific Advisory Board to Help CMT Research Foundation Deliver Treatments and Cures
The CMT Research Foundation is pleased to announce that Bruce D. Carter, Ph.D., has joined the organization’s Scientific Advisory Board to help guide research strategy and funding to deliver treatments and cures for Charcot-Marie-Tooth (CMT) disease. Dr. Carter is a...
Peter J. deSilva Joins CMT Research Foundation Board of Directors to Help Speed Treatments & Cures
The CMT Research Foundation is pleased to welcome Peter J. deSilva as the newest member of its board of directors. With more than 30 years of experience as a results-oriented leader in the financial sector, Mr. deSilva will bring his world-class expertise in strategic...Progress is Possible Because of You
As we begin 2021, I am overwhelmed with gratitude for your continued commitment to the CMT Research Foundation community. Despite a challenging last year, friends like you rose to the challenge and have made it possible for the CMT Research Foundation to fund new and...
How to Measure Progress in CMT Research: 8 Signs Research is Working
By: Susan Ruediger, CEO, CMT Research Foundation It costs more than $2.6 billion to develop an approved prescription medicine (Journal of Health Economics, 2016) and typically takes between 10 to 15 years to get a drug to clinical trials (Neuron, 2014). With no...
More Than Hope: An Action Plan to End CMT
By: Susan Ruediger, CEO, CMT Research Foundation As we approach the end of 2020 and look ahead to a new year, it’s natural to feel hopeful about what the future may hold — hope for an end to the global pandemic; hope for happiness and good health for our families; and...
Important Research News Announcements
- Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study January 9, 2021
- Epigenetic Regulation of CMT: A Lesson from Drosophila Models January 7, 2021
- Clinical features of homozygous FIG4-p.Ile41Thr Charcot-Marie-Tooth 4J patients January 6, 2021
- Aberrant Splicing in GJB1 and the Relevance of 5′ UTR in CMTX1 Pathogenesis December 28, 2020
- Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease December 20, 2020
- Neurogene adds another $115M to the pot for trials for its gene therapies, including its CMT4J program December 18, 2020
- More Than Hope: An Action Plan to End CMT December 18, 2020
- Aminoacyl-tRNA synthetases in Charcot-Marie-Tooth disease: a gain or a loss? November 26, 2020
- The expanding genetic landscape of hereditary motor neuropathies November 19, 2020
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Type 1A (CMT1A) November 19, 2020